Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Frederick Ruberg MD

Frederick L. Ruberg MD

Associate Chief, Section of Cardiovascular Medicine, and Associate Professor of Medicine and Radiology, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts

Frederick L. Ruberg, MD, is an Associate Professor of Medicine and Radiology at Boston University (BU) School of Medicine and clinical cardiologist at Boston Medical Center (BMC), specializing in cardiac imaging and infiltrative heart disease. He attended the University of Pennsylvania School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center. Dr. Ruberg has an active clinical practice as the senior cardiologist in the BU Amyloidosis Center. He is Associate Chief of Cardiovascular Medicine for Academic Affairs, Co-Director of the Cardiovascular Medicine Fellowship program, director of the cardiac MRI program at BMC as well as the Integrated Pilot Grants Program of the Boston University Clinical and Translational Science Institute. Dr. Ruberg is also an Associate Editor of Circulation: Cardiovascular Imaging and a Fellow of the American Heart Association. His NIH-funded research program focuses on the application of non-invasive cardiac imaging for amyloidosis identification and clinical care optimization. In addition, Dr. Ruberg’s area of research interest is ATTR amyloidosis, and in particular the inherited form of disease (hATTR or ATTRv). Current projects involve the application of pyrophosphate imaging for detection of ATTR amyloidosis, application of echocardiographic strain imaging as a disease marker, and validation of point of care diagnostic tools for cardiac amyloidosis identification in the outpatient clinic. Dr. Ruberg is committed to raising awareness of cardiac amyloidosis among clinicians and the general population so as to afford early diagnosis and enhanced access to disease modifying therapies.


Dr. Ruberg receives grant funding from Pfizer, Alnylam Therapeutics, and Akcea Therapeutics, NIH/NHLBI all for projects involving ATTR amyloidosis.